Kansai Medical University Hospital administers world’s first dose of DS1025 in an international early phase 1 clinical trial
DS1025, a CD25-directed antibody drug conjugate, targets immunosuppressive regulatory T cells in the tumor microenvironment, aiming to reduce a mechanism that can limit the body's immune response against cancer. The trial is an international effort to investigate DS1025 in patients with advanced solid tumors.